Currently, the most frequently used biomarkers (e.g., Aβ and tau) for AD can only be found using neuroimaging and examination of the cerebrospinal fluid (CSF); these are invasive, expensive, and specialized techniques, which makes them challenging to use in mass screening (5). This evidence concerns the gene MAPT and Alzheimer disease.